# HCA Healthcare, Inc.: Form 10-Q for the period ended Sep 30, 2022

- Company: [HCA Healthcare, Inc.](/companies/hca.md) (CIK 860730)
- Form: 10-Q
- Filed: 2022-11-01
- Accepted by EDGAR: Nov 1, 2022, 16:31 ET
- Period: 2022-09-30
- Accession: 0000950170-22-020865
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/860730/000095017022020865/hca-20220930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/860730/000095017022020865/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-07-01 to 2022-09-30 | $14.97bn | us-gaap:Revenues |
| Revenue | 9 months, 2022-01-01 to 2022-09-30 | $44.74bn | us-gaap:Revenues |
| Interest expense | 3 months, 2022-07-01 to 2022-09-30 | $446.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2022-01-01 to 2022-09-30 | $1.29bn | us-gaap:InterestExpense |
| Income tax | 3 months, 2022-07-01 to 2022-09-30 | $360.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2022-01-01 to 2022-09-30 | $1.09bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-07-01 to 2022-09-30 | $1.13bn | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-01-01 to 2022-09-30 | $3.56bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-07-01 to 2022-09-30 | $3.91 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2022-01-01 to 2022-09-30 | $11.97 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-07-01 to 2022-09-30 | $3.97 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2022-01-01 to 2022-09-30 | $12.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-07-01 to 2022-09-30 | 289,852,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-01-01 to 2022-09-30 | 297,702,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-01-01 to 2022-09-30 | $6.00bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2022-01-01 to 2022-09-30 | $3.07bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2022-01-01 to 2022-09-30 | $497.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months, 2022-01-01 to 2022-09-30 | $5.48bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2022-09-30 | $999.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-09-30 | $13.48bn | us-gaap:AssetsCurrent |
| Total assets | at 2022-09-30 | $51.48bn | us-gaap:Assets |
| Current liabilities | at 2022-09-30 | $9.78bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2022-09-30 | $37.49bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2022-09-30 | $218.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2022-09-30 | −$3.37bn | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/860730/000095017022020865/hca-20220930.htm

Filed Nov 1, 2022.
Source: SEC EDGAR, the filing index for accession 0000950170-22-020865. Last ingested by Listed: Nov 11, 2026, 03:15 ET. No prices; not investment advice.
